Jonathan Wolleben’s rating is based on the significant potential he sees in Structure Therapeutics, Inc., particularly due to its position as a leader in small molecule amylin agonists.

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

Conference call scheduled for 4:30 p.m. ET today Initiation of Phase 3 Studies for Subcutaneous VK2735 for Obesity Planned for 2Q25 Phase 2 VENTURE-Oral Dosing Trial ...

Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its ...

VK2809 is an orally available small molecule agonist of the thyroid ... we announced data from a new program targeting novel agonists of the amylin receptor for the potential treatment of obesity.

Dual Amylin and Calcitonin Receptor Agonist (DACRA ... Viking is also developing VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment ...